GenPhase delivers expert-led oncology trial imaging, powered by ONIX AI™.
From image review to signed reads, with a traceable audit trail—one accountable partner.
RECIST 1.1 draws the line at a 30% reduction in sum of diameters. A 28% reduction is clinically meaningful and commercially worthless. Sponsors who fall short need depth-of-response evidence that a binary call does not provide.
Under immunotherapy, tumors can enlarge and new lesions can appear before disease shrinks or resolves. Patients are told they progressed and come off therapy, and sites are not consistently trained to recognize the pattern.
A patient with no measurable disease at baseline enrolls, and it surfaces only at central adjudication — after dosing. The cost is a lost complete response, a paid re-adjudication, and contaminated efficacy data.
You are building a pipeline drug, not an imaging operation. We run the entire imaging execution layer of your trial: central reads, adjudication, quality control, structured data delivery under your data transfer plan, and the audit trail your submission depends on, so your team stays focused on the science.
See Biopharma ServicesWe are not asking you to adopt a platform. We are asking you to subcontract imaging execution: structured deliverables, on time, with a clean audit trail. Your coordinators never log in.
See CRO ServicesONIX AI™ is the environment the read happens in, not an analysis layer bolted onto someone else's viewer. It is the platform the read runs on, from image receipt to signed, structured data: a Read Environment, an Intelligence Layer, and a Governance Layer, in one platform.
ONIX AI Teleradiology serves hospitals and diagnostic centers in India with the platform and X-ray, CT and MRI reads signed by GenPhase radiologists under an SLA. One core, two product lines: every clinical read hardens the platform trials run on. Hospital data stays the hospital’s.
Learn more at onixai.inNot the imaging program. One question, answered on a defined scope, where value is visible in weeks.
Measurable disease, absence of disease in recurrence studies and brain metastasis status, confirmed centrally before a patient is dosed.
Central reads for Phase I and II programs where blinded independent central review is not required.
An independent read before a patient is taken off treatment.
Seasoned executives and credentialed clinicians united by a passion for compliant, scalable clinical imaging delivery.
Chief Executive Officer
Bill is a builder of enterprise technology businesses who has spent his career turning complex software into scaled commercial success. He is a sought-after voice on AI in clinical trials and steers GenPhase's growth and sponsor partnerships.
Chief Technology Officer
Krishna is the founder and architect of ONIX AI™, with a decade of building AI for regulated healthcare at Roche/Genentech and Mayo Clinic. He holds an MS in Biomedical Engineering from Carnegie Mellon University and has published oncology AI research with pharma collaborators, including RET alteration detection from H&E (Artificial Intelligence in Precision Oncology 2024; AACR 2023; SITC 2024), work in oncology AI and biomarker prediction.
Head of Clinical Operations, India
Dr. Kumar earned his MBBS at Maulana Azad Medical College and an MD in Anesthesia and Critical Care at PGIMER Chandigarh, and was a Senior Resident at AIIMS New Delhi. He completed an executive program at IIT Delhi and leads GenPhase’s clinical operations in India.
Scientist, Oncology
Dr. Sam holds a PhD in medicinal and pharmaceutical chemistry from the National University of Singapore and has more than 30 years in pharmaceutical research and drug discovery, in oncology since 2006, at AstraZeneca, S*BIO and the National University of Singapore. He is now focused on AI and data analytics for oncology research.
Lead Radiologist, India
Dr. Shashank earned his MBBS and MD in Radiodiagnosis at Maulana Azad Medical College, entering the MBBS program on an All India Rank of 130. His MD thesis evaluated soft-tissue masses using multiparametric 3T MRI. He served as Senior Resident at Lok Nayak Hospital, New Delhi, from 2023 to 2025, reading across all modalities at a tertiary care teaching center.
Oncology Radiologist
An AIIMS-trained oncology radiologist, Dr. Kumar brings focused expertise in cancer CT and MRI. Fluent in RECIST and trial response criteria, he delivers the precision that sponsors' endpoints depend on.
Oncology Radiologist
Dr. Kavita holds an MBBS from Army College of Medical Sciences, an MD in Radio-Diagnosis from ABVIMS & Dr. Ram Manohar Lohia Hospital, New Delhi, and a DNB in Radio-Diagnosis — dual credentials few radiologists carry. Three and a half years as senior resident at RML built high-volume CT and MRI expertise at one of Delhi's busiest tertiary hospitals, which she now brings to oncology reads at GenPhase.
Clinical Advisor
Chief Clinical Officer – Translational Medicine at Oncotelic Therapeutics, with more than thirty years initiating and overseeing oncology clinical trials. He was formerly SVP Clinical Research at Northwest Biotherapeutics and President of CancerVax.
Advisor
About twenty-two years across Eli Lilly, Bayer, Genentech and BioMarin in portfolio strategy and business development.
Advisor
VP and Head of Digital Strategy, Analytics and Programming at Exelixis, with more than 25 years in R&D data strategy and multiple oncology submissions.
Thought leadership from our clinical and technical team on imaging compliance, imaging core lab operations, and regulated research technology.
Progression is the call that ends treatment. Under immunotherapy it is the call most often made too early. What an independent progression read needs, and five questions to put to whoever reads your study.
Read More
A 28% reduction in sum of diameters is clinically meaningful. To an investor it is a miss. Why RECIST's thresholds strain under financing decisions they were never built for.
Read More
FDA investigators found tumor growth rate inversely associated with survival in metastatic NSCLC. What that finding actually supports — and the four things it does not establish.
Read More
Seven areas worth requiring specifics on before site activation, and the questions that get you those specifics — from acquisition deviations to who signs the report. Written for the sponsor, not about GenPhase.
Read More
Where AI delivers measurable impact — strategic use cases, the economics of AI-native vs. legacy imaging operations, and a practical implementation roadmap.
Read MoreEarly AI adoption automated isolated tasks. The real shift is a read environment built for imaging from the ground up — redesigning the workflow around better decision-making, predictive capability, and adaptive execution.
Read More
How ONIX AI's integrated platform is streamlining clinical imaging workflows — improving pre-read QC, case routing, structured reporting, and BICR management across multi-site trials.
Read More
Bill Draper and Keleni Tukia, MD MBA MPH share what they heard at the BIO International Convention 2026 in San Diego — and why clinical trial imaging is at a genuine inflection point.
Read More
Protocol deviations caught after a radiologist reads the scan cost time, inflate query volume, and create inspection risk. A protocol-aware pre-read QC gate changes all three — here’s how it works in practice.
Read More
AI can reduce manual workload and accelerate reads, but in regulated research it must not obscure clinician accountability. Here’s how to build workflows where AI amplifies clinical judgment while preserving GCP and 21 CFR Part 11 compliance.
Read More
As clinical trials become more complex and competitive, the role of medical imaging has never been more critical. If you’re experiencing any of these five red flags, it may be time to re-evaluate your imaging strategy.
Read More
Clinical research is becoming increasingly data-intensive and operationally complex. Medical imaging is playing a growing role in evaluating treatment efficacy, monitoring safety, and supporting regulatory submissions across a wide range of therapeutic areas.
Read More
Over the past several years, clinical imaging has evolved from a supporting trial function into a critical determinant of operational performance. In 2026, that shift is no longer emerging.
Read MoreWhat happens next. Send us the protocol and the enrollment timeline. Our clinical team responds within one business day, and you will have a scoped plan and pricing within five business days.
1990 N California Blvd., 8th Floor
Walnut Creek, CA 94596
(844) 922-7468
hello@genphase.ai
Fill out the form and a member of our clinical team will respond within one business day.
By submitting this form, you agree to let GenPhase use the information provided to send relevant content about our products and services. You can unsubscribe at any time.
The modern alternative to legacy imaging CROs.
Built for the teams changing medicine.